Intrasense, a French expert in medical imaging solutions facilitating and securing diagnosis, decision-making, and treatment follow-up, announces the publication of its 2025 half-year results and progress on its strategic roadmap. These accounts were approved on September 24, 2025, by the Board of Directors.

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert in AI-enhanced medical imaging solutions that facilitate diagnostics, decision-making, and therapeutic follow-up, announces the CE marking under MDR (Medical Device Regulation) for DUOnco™ Pancreas, marking a new milestone in its innovation strategy focused on oncology follow-up.

Intrasense, a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making, and therapeutic follow-up, announces its consolidated sales for the first half of fiscal year 2025.

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian^® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions is fully in line with the Group's strategic roadmap, based on four pillars: innovation, product range extension, geographical expansion and financial control.

Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the certification report was issued on March 26 by the statutory auditors.